Effect of spironolactone in CV Mortality in hemodialysis patients

Journal of the American College of Cardiology

Volumn 64, Issue 5, 2014, Pages 528-529

  Kannan, Arun ^a   Poongkunran, Chithra ^b   Balamuthusamy, Saravanan ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; SPIRONOLACTONE;

ALBUMIN BLOOD LEVEL; BONE METABOLISM; BONE MINERAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; END STAGE RENAL DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LETTER; MORBIDITY; NUTRITIONAL STATUS; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK REDUCTION; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE;

EID: 84905171831     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.03.053     Document Type: Letter

References (2)

1. Y. Matsumoto, Y. Mori, and S. Kageyama et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients J Am Coll Cardiol 63 2014 528 536
2. B. Pitt, F. Zannad, and W.J. Remme et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717